The relevance of using 5α-reductase inhibitors in the conservative management of benign prostatic hyperplasia: A review

The incidence of benign prostatic hyperplasia is increasing annually, affecting progressively younger age groups. These epidemiological shifts necessitate a deeper investigation into the pathogenesis of the disease to identify its key mechanisms and develop effective pharmacological treatment approaches. Recently, 5α-reductase inhibitors have become particularly relevant for managing lower urinary tract symptoms (LUTS) caused by BPH. Appropriate dosing and duration of therapy with this drug class not only slow disease progression but also effectively prepare patients for surgical intervention, reducing the risks of peri- and postoperative complications. This article explores not only the role of 5α-reductase inhibitors in treating LUTS but also their potential use for managing other conditions, such as prostate cancer chemoprevention or androgenetic alopecia treatment.